Iovance Projects $350-370M 2026 Revenue, IOV-END-201 Shows 40% ORR; UK Amtagvi Application Withdrawn
Summary
Iovance Biotherapeutics reported strong Q1 2026 revenue and provided fiscal 2026 revenue guidance of $350–$370 million. The company also announced positive early clinical data for IOV-END-201, showing a 40% confirmed objective response rate and 100% disease control in the first five serous endometrial cancer patients. However, Iovance simultaneously disclosed the withdrawal of its UK marketing application for Lifileucel (Amtagvi) due to procedural issues, with plans to discuss resubmission. This update expands significantly on earlier Q1 financial disclosures from today's 10-Q and 8-K filings by adding critical forward-looking guidance, new pipeline data, and a notable regulatory setback. The 2026 revenue guidance and positive clinical data offer a positive outlook for future growth, while the Amtagvi withdrawal introduces uncertainty regarding international market expansion for a key product. Investors will closely watch for updates on the UK resubmission and further clinical trial progress.
At the time of this announcement, IOVA was trading at $3.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $1.64 to $5.63. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.